Format

Send to

Choose Destination
See comment in PubMed Commons below
Brachytherapy. 2015 Mar-Apr;14(2):166-72. doi: 10.1016/j.brachy.2014.11.015. Epub 2015 Jan 9.

Permanent seed brachytherapy for clinically localized prostate cancer: long-term outcomes in a 700 patient cohort.

Author information

1
Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
2
Department of Radiation Oncology, Policlinico di Palermo, Universitá degli Studi di Palermo, Palermo, Italy.
3
Department of Medical Physics, Catalan Institute of Oncology, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
4
Department of Urology, Hospital de Bellvitge, Barcelona, Spain.
5
Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
6
Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: guedea@iconcologia.net.

Abstract

PURPOSE:

Few large European studies have evaluated long-term outcomes for permanent prostate brachytherapy (PPB) as monotherapy for clinically localized prostate cancer. The objective of the present study was to evaluate long-term survival in this patient profile.

METHODS AND MATERIALS:

Retrospective study of 700 patients who underwent transperineal ultrasound-guided iodine-125 PPB (145 Gy) between January 2000 and July 2012. Median age was 64.8 years (range, 35-79). Most patients (638 of 700; 91%) had low-risk disease (D'Amico criteria). Eighty-five patients (12%) received hormonal treatment. Overall survival, cause-specific survival, and biochemical relapse-free survival were calculated and estimated using actuarial and Kaplan-Meier methods. Differences between groups were assessed using the log-rank test.

RESULTS:

Median followup was 63 months (range, 6-164). At 5- and 10-year followup, respectively, overall survival was 94% (95% confidence interval [CI], 92-96) and 84% (95% CI, 78-90); cause-specific survival was 100% and 97% (95% CI, 95-99); and biochemical relapse-free survival was 95% (95% CI, 93-97) and 85% (95% CI, 79-91).

CONCLUSIONS:

The long-term results presented in this report confirm previous studies and provide additional support for the use of PPB in patients with favorable-risk prostate cancer. Seed brachytherapy provides excellent long-term results in this patient profile.

KEYWORDS:

Biochemical outcome; Brachytherapy; Clinically localized; Prostate cancer; Seed implant

PMID:
25582682
DOI:
10.1016/j.brachy.2014.11.015
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center